What changed in this filing

/stocks — the workspaceLOADING

Item 2. Management’s Discussion and Analysis

2022-05-03 compared with 2021-11-04 · 181 added, 197 removed, 139 unchanged (73% of the section changed)

4 unchanged sentences

You should be aware that the forward-looking statements included herein represent management’s current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements.

Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, as updated by the risks reported in our Quarterly Reports on Form 10-Q, in any prospectus or prospectus supplement filed with the SEC pursuant to Rule 424(b) under the Securities Act of 1933, as amended, and in the press releases and other communications to stockholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business.

Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, as updated by any risks reported in our Quarterly Reports on Form 10-Q and in the press releases and other communications to stockholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business.

We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.

This discussion of our financial condition and the results of operations should be read together with the financial statements, including the notes contained elsewhere in this Quarterly Report on Form 10-Q, and the financial statements, including the notes thereto, contained in our Annual Report on Form 10-K for the year ended December 31, 2020, as filed with the SEC on March 9, 2021.

We are a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery.

We are investigating and commercializing our blood purification technology to reduce deadly uncontrolled inflammation in hospitalized patients around the world, with the goal of preventing or treating multiple organ failure in life-threatening illnesses and cardiac surgery.

Organ failure is the cause of nearly half of all deaths in the intensive care unit (“ICU”), with little to improve clinical outcome.

CytoSorb, our flagship product, is approved in the European Union (“EU”) as an extracorporeal cytokine adsorber and is designed to reduce the “cytokine storm” that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis.

We are a leader in the treatment of life-threatening conditions in the intensive care (“ICU”) and cardiac surgery using blood purification via our proprietary polymer adsorption technology.

We have a number of products commercialized and in development based on this technology platform.

Our flagship product, CytoSorb®, is already commercialized, and is being investigated to reduce deadly uncontrolled inflammation and dangerous substances in hospitalized patients around the world, with the goal of preventing or treating multiple organ failure, bleeding, and other potentially fatal complications.

Organ failure is the cause of nearly half of all deaths in the ICU, with little to improve clinical outcome.

CytoSorb, is approved in the European Union (“EU”) as an effective extracorporeal cytokine absorber, designed to reduce the “cytokine storm” or “cytokine release syndrome” that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, cytokine release syndrome due to cancer immunotherapy, and pancreatitis.

These are conditions where the mortality is extremely high, yet few to no effective treatments exist.

In May 2018, we received a label expansion for CytoSorb covering use of the device for the removal of bilirubin and myoglobin in the treatment of liver disease and trauma, respectively.

In January 2020, we received a further EU label expansion for CytoSorb to remove the anti-platelet agent, ticagrelor, during urgent and emergent cardiothoracic surgery on cardiopulmonary bypass.

In May 2020, we received another EU label expansion for CytoSorb to remove rivaroxaban, a Factor Xa inhibitor, for the same indication.

In April 2020, the Company announced that the FDA had granted CytoSorbents’ technology Breakthrough Designation for the removal of ticagrelor in a cardiopulmonary bypass circuit during emergent and urgent cardiothoracic surgery.

In January 2020, we received CE-Mark label expansion for CytoSorb covering the use of the device for the removal of the anti-platelet agent, ticagrelor, in patients undergoing surgery requiring cardiopulmonary bypass.

In April 2020, the United States Food and Drug Administration (the “FDA”) granted CytoSorbents’ technology Breakthrough Device Designation for the removal of ticagrelor in a cardiopulmonary bypass circuit during emergent and urgent cardiothoracic surgery.

If FDA marketing approval for this indication is obtained, the device would be marketed as DrugSorb-ATR in the United States.

The DrugSorb-ATR Antithrombotic Removal System is based on the same polymer technology as CytoSorb.

We believe the current addressable market in the United States for ticagrelor removal in cardiac surgery is approximately $250 million based on our current pricing model, assuming FDA marketing approval, that could expand to $500 million should ticagrelor gain market share as the only reversible mainstream anti-platelet agent.

In August 2021, the Company announced that it has been granted a second Breakthrough Device designation for its DrugSorb-ATR Antithrombotic Removal System by the U.S.

Food and Drug Administration (FDA).

This Breakthrough Device designation covers the removal of the Direct Oral Anticoagulants (DOACs) apixaban and rivaroxaban in a cardiopulmonary bypass circuit to reduce the likelihood of serious perioperative bleeding during urgent cardiothoracic surgery.

In the event that DrugSorb-ATR also obtains FDA marketing approval to remove the DOACs apixaban and rivaroxaban, we believe the total addressable market in the United States for ticagrelor and DOAC removal during cardiothoracic surgery could potentially increase to approximately $1.0 billion.

In the event that DrugSorb-ATR obtains FDA marketing approval to be used prophylactically to remove ticagrelor apixaban and rivaroxaban in all patients undergoing surgery, we believe it would potentially expand the total addressable market in the United States to approximately $2.0 billion.

In April 2020, we announced that the U.S.

FDA has granted U.S.

Emergency Use Authorization (“EUA”) of CytoSorb for use in critically ill patients with COVID-19 infection and respiratory failure.

In May 2020, we received a CE-Mark label expansion for CytoSorb for the removal of rivaroxaban during cardiothoracic surgery requiring cardiopulmonary bypass.

In August 2021, the Company announced that it was granted a second Breakthrough Device Designation for its DrugSorb-ATR Antithrombotic Removal System by the FDA to remove the direct oral anticoagulants, rivaroxaban and apixaban.

The Company has initiated two U.S.

clinical trials evaluating the use of DrugSorb-ATR during cardiothoracic surgery to remove ticagrelor, apixaban and rivaroxaban to prevent or reduce perioperative bleeding complications in pursuit of U.S.

FDA marketing approval.

CytoSorb is used during and after cardiac surgery to remove inflammatory mediators, such as cytokines, activated complement, and free hemoglobin that can lead to post-operative complications such as acute kidney injury, lung injury, shock, and stroke.

We believe CytoSorb has the potential to be used in many other inflammatory conditions, including the treatment of autoimmune disease flares, cytokine release syndrome in cancer immunotherapy, and other applications in cancer, such as cancer cachexia.

More than 152,000 CytoSorb devices have been utilized to date in critical illnesses and in cardiac surgery.

CytoSorb has been used globally in more than 170,000 human treatments to date in critical illnesses and in cardiac surgery.

CytoSorb has received CE-Mark label expansions for the removal of bilirubin (liver disease), myoglobin (trauma) and both ticagrelor and rivaroxaban during cardiothoracic surgery.

CytoSorb has also received FDA Emergency Use Authorization (EUA) in the United States for use in adult critically-ill COVID-19 patients with imminent or confirmed respiratory failure, in defined circumstances.

CytoSorb has also received FDA Emergency Use Authorization in the United States for use in critically ill COVID-19 patients with imminent or confirmed respiratory failure, in defined circumstances.

The EUA will be effective until a declaration is made that the circumstances justifying the EUA have terminated or until revoked by the FDA.

CytoSorb has been used globally in more than 7,650 human treatments to date in COVID-19 patients.

CytoSorbents’ technology has also been granted two FDA Breakthrough Designations for the removal of ticagrelor and the removal of the direct oral anticoagulants (“DOACs”) apixaban and rivaroxaban in a cardiopulmonary bypass circuit during urgent cardiothoracic surgery, and if FDA marketing approval is obtained for these indications, the device would be marketed as the DrugSorb-ATR Antithrombotic Removal System in the United States.

In July 2021, the Company received full approval of its Investigational Device Exemption (“IDE”) by the FDA to conduct the pivotal STAR-T (Safe and Timely Antithrombotic Removal – Ticagrelor) double-blind, randomized control trial (“RCT”) for up to 120 patients in the United States to support FDA marketing approval.

In October 2021, the Company also received full FDA approval of an IDE application to conduct a double-blind, randomized, controlled clinical study for up to 120 patients entitled, “Safe and Timely Antithrombotic Removal – Direct Oral Anticoagulants (STAR-D),” in the United States to support FDA marketing approval.

We are focusing on four key objectives that we believe are the key to driving sustainable, long-term growth:

• Open the U.S.

market by obtaining FDA Marketing approval for DrugSorb™-ATR to remove blood thinning drugs during cardiothoracic surgery (see clinical studies update)

• Grow core CytoSorb sales to profitability, driven by numerous internal initiatives (sales and marketing update)

• Transition CytoSorb production to our new manufacturing facility and headquarters in Princeton, New Jersey this year

• Forge and expand new and existing strategic partnerships to maximize the synergy between our technology and those of our partners, while creating new global opportunities for growth

Our purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.

2 unchanged sentences

and internationally.

In October 2020, we announced the E.U.

approval of the ECOS-300CY™ adsorption cartridge for use with ex vivo organ perfusion systems to remove cytokines and other inflammatory mediators in the organ perfusate, with the goal of improving solid organ support or rehabilitation.

We have numerous other product candidates under development based upon this unique blood purification technology, including CytoSorb XL, K + ontrol, HemoDefend-RBC, HemoDefend-BGA, ContrastSorb, DrugSorb, DrugSorb-ATR and others.

In March 2011, CytoSorb was “CE Marked” in the E.U.

as an extracorporeal cytokine adsorber indicated for use in clinical situations where cytokines are elevated, allowing for commercial marketing.

The CE Mark demonstrates that a conformity assessment has been carried out and the product complies with the Medical Devices Directive.

The goal of CytoSorb is to prevent or treat organ failure by reducing cytokine storm and the potentially deadly systemic inflammatory response syndrome (“SIRS”) in diseases such as sepsis, trauma, burn injury, acute respiratory distress syndrome, pancreatitis, liver failure, and many others.

Organ failure is the leading cause of death in the ICU, and remains a major unmet medical need, with little more than supportive care therapy (e.g., mechanical ventilation, dialysis, vasopressors, fluid support, etc.) as treatment options.

By potentially preventing or treating organ failure, CytoSorb may improve clinical outcome, including survival, while reducing the need for costly ICU treatment, thereby potentially saving significant healthcare costs.

The market focus for CytoSorb is the prevention or treatment of organ failure in life-threatening conditions, including commonly seen illnesses in the ICU such as infection and sepsis, trauma, burn injury, acute respiratory distress syndrome (“ARDS”), and others.

Severe sepsis and septic shock, a potentially life-threatening systemic inflammatory response to a serious infection, accounts for approximately 10% to 20% of all ICU admissions and is responsible for an estimated one in every five deaths worldwide.

Sepsis is one of the largest target markets for CytoSorb.

Sepsis is a major unmet medical need with no approved products in the U.S.

or Europe to treat it.

As with other critical care illnesses, multiple organ failure is the primary cause of death in sepsis.

When used with standard of care therapy, that includes antibiotics, the goal of CytoSorb in sepsis is to reduce excessive levels of cytokines and other inflammatory toxins, to help reduce the SIRS response and either prevent or treat organ failure.

We intend to conduct or support additional clinical studies in the future in the core applications of critical care medicine and cardiac surgery.

We intend to generate additional clinical data to expand the scope of clinical experience for marketing purposes, to increase the number of treated patients, and to support potential future regulatory submissions.

Our proprietary polymer technologies form the basis of a broad technology portfolio.

2 unchanged sentences

• DrugSorb-ATR — an investigational extracorporeal antithrombotic removal system based on the same polymer technology as CytoSorb that is being evaluated in the U.S.

STAR-T and STAR-D pivotal randomized, controlled trial to reduce the antithrombotic drugs, ticagrelor, apixaban and rivaroxaban to reduce bleeding complications in patients undergoing cardiothoracic surgery while on these drugs.

STAR-T and STAR-D pivotal randomized, controlled trials to reduce the level of antithrombotic drugs, ticagrelor, apixaban and rivaroxaban to reduce bleeding complications in patients undergoing cardiothoracic surgery while on these drugs.

• ECOS-300CY — an adsorption cartridge approved in the E.U.

for use with ex vivo organ perfusion systems to remove cytokines and other inflammatory mediators in the organ perfusate, with the goal of improving solid organ support or rehabilitation.

for use with ex vivo organ perfusion systems to remove cytokines and other inflammatory mediators in the organ perfusate, with the goal of maintaining or improving solid organ function.

In 2021, commercialization of PerSorb™ and Aferetica’s PerLife™ ex vivo organ perfusion system commenced in Italy.

• CytoSorb XL — an intended next generation successor to CytoSorb currently in advanced pre-clinical testing designed to reduce a broad range of cytokines and inflammatory mediators, including lipopolysaccharide endotoxin, from blood.

11 unchanged sentences

For a complete discussion regarding our clinical study history, please refer to the section entitled Clinical Studies included in Item 1 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 as filed with the SEC on March 10, 2022.

The following discusses the status of our clinical studies subsequent to the filing of the Company’s Annual Report on Form 10-K:

The REFRESH 2-AKI study in the United States has resumed enrollment at multiple trial centers and has reached enrollment of 178 subjects.

After accounting for the required roll-ins at each site and some enrolled patients who ultimately did not undergo the scheduled procedure, a total of 111 patients have been randomized as of November 1, 2021.

The goal of the study is to achieve the milestone of the interim analysis in 2022, however, the ongoing COVID-19 pandemic is causing enrollment delays associated with postponement or deferral of elective cardiac surgeries and shortage in research staff, creating uncertainty of this target .

The following includes certain updates regarding these clinical studies subsequent to the filing of the Company’s Annual Report on Form 10-K:

In July 2021, we received full FDA approval of an Investigational Device Exemption (IDE) application to conduct a double-blind, randomized, controlled clinical study for up to 120 patients entitled, “ S afe and T imely A ntithrombotic R emoval – T icagrelor ( STAR-T ),” in the United States to support FDA marketing approval.

This was done under the previously announced FDA Breakthrough Designation granted for the removal of ticagrelor in a cardiopulmonary bypass circuit during urgent and emergent cardiac surgery.

This was done under the previously announced FDA Breakthrough Device Designation granted for the removal of ticagrelor in a cardiopulmonary bypass circuit to reduce the likelihood of serious perioperative bleeding during urgent cardiac surgery.

In October 2021, the first patient was enrolled and the STAR-T study is now actively recruiting at multiple sites.

Pending any COVID-19 related delays we expect that the study will complete enrollment in 2022.

In October 2021, we received full FDA approval of an Investigational Device Exemption (IDE) application to conduct a double-blind, randomized, controlled clinical study for up to 120 patients entitled, “ S afe and T imely A ntithrombotic R emoval – D irect Oral Anticoagulants T icagrelor ( STAR-D ),” in the United States to support FDA marketing approval.

This was done under the previously announced FDA Breakthrough Designation granted for our DrugSorb-ATR Antithrombotic Removal System.

Study start-up activities have begun with enrollment expected to begin in the first quarter of 2022.

In April 2020, we received Emergency Use Authorization for the treatment of adult critically ill COVID-19 patients with evidence of hyperinflammation and confirmed or imminent respiratory failure.

The C ytoSorb T herapy in C OVID-19 ( CTC ) Registry was launched to capture outcomes and device utilization patterns from multiple US participating centers.

Primary results on observed ICU mortality of COVID-19 patients with acute respiratory distress syndrome (ARDS) requiring extracorporeal membrane oxygenation (ECMO) and treated with CytoSorb according to FDA Emergency Use Authorization criteria were presented at the International Symposium of Intensive Care Medicine conference at the end of August 2021 in Brussels, Belgium, and have also been submitted for journal publication.

CYTATION (CytoSorb Ticagrelor Hemoadsorption) is a company-sponsored multicenter study in Germany to prospectively evaluate the removal of ticagrelor during emergent cardiothoracic surgery.

The study is actively recruiting patients at all 3 German sites plus a recently added clinical site in Luxembourg.

Pending any uncertainty introduced by COVID-19 related delays we expect that the study will complete enrollment in 2022.

The German PROCYSS multicenter, randomized controlled trial evaluating the ability of CytoSorb to restore hemodynamic stability in patients with refractory septic shock is now actively recruiting.

The speed of enrollment remains uncertain due to COVID-19, however we currently estimate completion of the study by end of 2023.

The German multicenter Hep-On-Fire single-arm trial evaluating CytoSorb in patients suffering from acute liver failure due to alcoholic hepatitis has received Ethics Committee approval in October 2021.

Study start-up activities are ongoing, and we expect that the study will begin enrollment in the first quarter of 2022.

CytoSorb received European Union CE Mark label expansion for the removal of ticagrelor and rivaroxaban during cardiopulmonary bypass in patients undergoing cardiothoracic surgery in January 2020 and May 2020, respectively.

We designed the international, multicenter STAR ( S afe and T imely A ntithrombotic R emoval) Registry with the purpose of capturing real world clinical and economic outcomes in the antithrombotic removal application.

The registry is currently actively enrolling patients and we estimate that first data readouts from the STAR Registry will begin in 2022.

The German government-sponsored and investigator-initiated REMOVE all-comer endocarditis study presented topline results at the European Association of CardioThoracic Surgery (EACTS) annual meeting in Barcelona, Spain in October 2021.

The REMOVE investigators stated that although intraoperative hemoadsorption reduced plasma cytokines at the end of surgery it did not reduce the severity of post-operative organ dysfunction (primary outcome determined by change in SOFA score) or any of the secondary endpoints including 30-day mortality.

The investigators also concluded there was “no signal for harm due to the use of CytoSorb in patients undergoing surgery for infective endocarditis”.

The preliminary results abstract is available online and the authors stated that results have also been submitted for publication.

CytoSorbents is working collaboratively with the REMOVE investigators to conduct additional exploratory analyses to potentially identify subgroups that may have benefited from CytoSorb and to also inform potential future studies in this application.

Pending continuing uncertainty from the ongoing COVID-19 pandemic, we expect the study to reach its first scheduled milestone of 33% patient enrollment that will trigger the first Data Safety Monitoring Board (DSMB) meeting during the summer of 2022 and for the overall study enrollment to be complete in the first quarter of 2023.

In October 2021, we also received full FDA approval of an Investigational Device Exemption (IDE) application to conduct a double-blind, randomized, controlled clinical study for up to 120 patients entitled, “ S afe and T imely A ntithrombotic R emoval – D irect Oral Anticoagulants ( STAR-D ),” in the United States to support FDA marketing approval.

This was done under the previously announced 2 nd FDA Breakthrough Device Designation granted for our DrugSorb-ATR Antithrombotic Removal System.

The first sites have been activated and are actively recruiting.

The first patient was enrolled in April 2022 and pending the continuing uncertainty from the ongoing COVID-19 pandemic we expect the study to complete enrollment in 12-18 months.

In January 2020, CytoSorb received European Union CE Mark label expansion to include the removal of ticagrelor during cardiopulmonary bypass in patients undergoing cardiothoracic surgery.

In May 2020, CytoSorb also received European Union CE Mark label expansion to include rivaroxaban removal for the same indication.

The international S afe and T imely A ntithrombotic R emoval ( STAR ) Registry is designed to capture real world clinical and health economic outcomes with intraoperative antithrombotic drug removal.

The Registry is actively enrolling patients in the U.K.

and Germany and is planned to expand to additional EU countries before the end of 2022.

The intent of the Registry is to report outcomes at international conferences and submit the results for publication on a rolling basis as enrollment progresses.

In April 2020, we received U.S.

FDA Emergency Use Authorization for the treatment of adult critically ill COVID-19 patients with confirmed or imminent respiratory failure.

The C ytoSorb T herapy in C OVID-19 ( CTC ) Registry was launched to capture outcomes and device utilization patterns from multiple U.S.

participating centers.

Initial results on critically ill COVID-19 patients on extracorporeal membrane oxygenation (ECMO) treated with CytoSorb at participating U.S.

centers showed high survival rates compared with the international benchmark Extracorporeal Life Support Organization (ELSO) Registry.

The initial CTC results were presented at the International Symposium of Intensive Care Medicine conference in August 2021 in Brussels, Belgium, and published in the peer reviewed journal Frontiers in Medicine .

The CTC has completed enrollment and the final results will also be submitted for publication.

The German PROCYSS multicenter, randomized controlled trial evaluating the ability of CytoSorb to restore hemodynamic stability in patients with refractory septic shock is now actively enrolling at multiple sites.

The speed of enrollment remains uncertain due to COVID-19, however we currently estimate that the next important milestone of the interim analysis after 50% enrollment will occur in 2023.

The German multicenter Hep-On-Fire single-arm trial evaluating CytoSorb in patients suffering from acute liver failure due to alcoholic hepatitis received Ethics Committee approval in October 2021 and is currently actively recruiting.

We expect that the first patient will be enrolled in the study in the first half of 2022 and that the next important milestone of the interim analysis after 50% enrollment will occur in 2023.

The international COSMOS Registry was designed to capture real world outcomes and device utilization patterns across multiple critical care indications including but not limited to sepsis, acute respiratory failure, postoperative vasoplegia, acute liver failure, and acute pancreatitis.

The Registry is undergoing start-up activities and scheduled to begin enrollment in the first half of 2022 with the goal of being active in multiple countries in 2023.

The intent of the Registry is to report outcomes at international conferences and submit the results for publication on a rolling basis as enrollment progresses.

Sales and Marketing Update

The following are the key initiatives that we have been executing upon to drive product sales growth in the future.

Near-term growth drivers

• Resume In-person Sales from a Strong Customer Base:

Our core customer base accounts for the majority of our direct sales and grew by 20-25% at the start of the pandemic and has remained stable since.

We are in close contact with all of these accounts and have confirmed that COVID-19 related issues, including its effect on staffing and numbers of ICU patients, are the primary issue for volatility in ordering.

We believe a return to in-person selling will reinvigorate growth.

• New Therapy Divisions:

We have established three distinct therapy divisions within our commercial operations including Critical Care, Cardiovascular, and Liver/Kidney/other to develop these markets internationally with the focus of leaders with area-specific medical and commercial expertise, who will work closely with our sales teams and best serve the needs and interests of our customers.

We have already seen our efforts bear fruit with now more than 150 cardiac surgery centers internationally who have begun to use CytoSorb to remove antithrombotic drugs during urgent cardiac surgery, for example.

We believe this infrastructure will yield many more similar successes across a broad array of applications.

• New Exclusive Private Hospital Chain Partnerships:

We are now the preferred supplier of hemoadsorption technology to the three largest private hospital chains in Germany, including, as announced yesterday, Asklepios Kliniken GmbH, and the former hospitals of RHÖN-KLINIKUM AG.

Many of these hospitals are already current customers and our agreements facilitate access and sales of CytoSorb to these and all other relevant institutions within these hospital networks.

• Rise of Existing and New Applications:

Among the many applications, we highlight:

Many studies have highlighted the ability of CytoSorb to remove inflammatory mediators and help to stabilize shock, a potentially fatal drop in blood pressure, in a wide range of patients.

A recent 2019 meta-analysis, found that approximately 10% of ICU patients have septic shock at admission and 8% of patients admitted to the ICU have septic shock at some point in their hospital stay, with a high mortality of 38%.

CytoSorb is being used around the world as a treatment of shock and we are conducting the PROCYSS RCT to formally evaluate CytoSorb as a treatment of this common and major unmet medical need.

o Liver disease:

In the treatment of acute liver disease, CytoSorb outperforms the market leading MARS® platform (Baxter) in the in vitro removal of many liver toxins, but has the added benefit of removing cytokines and inflammatory mediators, while being much easier to use.

In real-world practice, CytoSorb has replaced MARS at many accounts.

o Lung Injury:

CTC registry highlights the high survival of critically ill COVID-19 patients with acute respiratory distress syndrome (ARDS) treated with CytoSorb and ECMO under FDA Emergency Use Authorization.

We believe these data demonstrate a therapeutic strategy of “enhanced lung rest” using the combined therapies that can be extrapolated to the treatment of ARDS in non-COVID patients, a very large market.

Longer-term growth drivers

• Stand-alone blood pump strategy:

There are many applications where a simple, low-cost hemoperfusion pump is adequate to implement our CytoSorb blood purification technology, without the complexity of a large dialysis or continuous renal replacement therapy (CRRT) machine, without the need for a dialysis technician, and where patients do not need to have failed kidneys.

This would greatly simplify treatment with CytoSorb in the ICU - potentially enabling its more ubiquitous and earlier use on more patients while opening the door for more new applications in the emergency room, surgery suites, and elsewhere, in what we call the “hospital-wide” application.

We have initially partnered with a major international dialysis company to distribute a high-quality hemoperfusion machine in Germany, Austria, and Luxembourg and are in the midst of a soft launch, to be followed by a broader rollout in these countries later this year, and in more countries in the not-to-distant future.

The machine is only as good as the therapy that is being run on it, and CytoSorb is the market leading cytokine adsorbing technology that makes this an excellent combination treatment and a potentially game-changing new business model going forward.

• Expansion of direct sales territories:

Although opening new countries with a direct sales force requires time, cost, and effort, it also allows us to directly lead the effort, drive results, and benefit from more profitable sales.

With the announcement of expansion of direct sales into the U.K.

and Ireland, we now sell direct in two of the E.U.’s Big 5 Economies - Germany and the U.K.

– and a total of 15 countries direct overall, while working with distributors or partners in the other three Big 5 Economies:

France, Italy, and Spain.

• Investment in important clinical studies in shock, liver failure, cardiac surgery, ATR, etc:

We are committed to funding Company-sponsored studies in key areas that we believe will drive international adoption and usage, with the goal of becoming a standard of care for those applications.

COVID-19 Business Update

1 unchanged sentence

a potentially fatal drop in blood pressure), kidney failure, acute cardiac injury, thromboses and emboli, and secondary bacterial infections.

The underlying cause for these complications is often a cytokine storm that results in a massive, systemic inflammatory response, leading to the damage of vital organs such as the lungs, heart, and kidneys, and ultimately multiple organ failure and death in many cases.

The underlying cause for these complications is often a massive, systemic inflammatory response, leading to the damage of vital organs such as the lungs, heart, and kidneys, and ultimately multiple organ failure and death in many cases.

Hypercoagulability, thought triggered by inflammation, and resulting thromboembolic events such as pulmonary emboli and thrombotic microangiopathy, play another critical role in the pathophysiology of COVID-19 infection and severity of illness.

The use of CytoSorb in patients infected with COVID-19 in Italy, China, Germany and France began in March 2020.

CytoSorb has now been used to treat dangerous inflammation and related life-threatening complications in approximately 6,900 COVID-19 patients in

more than 30 countries.

CytoSorb has now been used to treat dangerous inflammation and related life-threatening complications in more than 7,650 COVID-19 patients in more than 30 countries as of March 31, 2022.

Based upon initial data and reports from physicians treating these complications, CytoSorb use has generally been associated with a marked reduction in cytokine storm and inflammation, improved lung function, weaning from mechanical ventilation, decannulation from extracorporeal membrane oxygenation (ECMO), and a reversal of shock.

7 unchanged sentences

under the FDA’s Expanded Access Program (“EAP”).

On April 13, 2020, we announced that the FDA, in a different program than the EAP, granted Emergency Use Authorization (EUA) of CytoSorb for use in adult U.S.

COVID-19 patients.

On April 13, 2020, we announced that the FDA, in a different program than the EAP, granted U.S.

Emergency Use Authorization (EUA) of CytoSorb for use in adult critically ill COVID-19 patients.

Under the EUA, CytoSorbents can make CytoSorb available, through commercial sales, to all hospitals in the U.S.

3 unchanged sentences

The EUA will be effective until a declaration is made that the circumstances justifying the EUA have terminated or until revoked by the FDA.

The CTC (CytoSorb Therapy in COVID-19) Registry was launched to capture outcomes and device utilization patterns from multiple US participating centers.

The CTC (CytoSorb Therapy in COVID-19) Registry was launched to capture outcomes and device utilization patterns from multiple U.S.

participating centers.

Primary results on observed ICU mortality of COVID-19 patients with acute respiratory distress syndrome (ARDS) requiring extracorporeal membrane oxygenation (ECMO) and treated with CytoSorb according to FDA EUA criteria were presented at the International Symposium of Intensive Care Medicine conference in September 2021 in Brussels, Belgium.

In December 2021, we announced the publication of these results in the peer-reviewed journal Frontiers in Medicine .

Government Research Grants:

We have been successful in obtaining technology development contracts from governmental agencies such as the National Institutes of Health and the U.S.

We have historically been successful in obtaining technology development contracts from governmental agencies such as the National Institutes of Health and the U.S.

Department of Defense, including the Defense Advanced Research Projects Agency (“DARPA”), the U.S.

Special Operations Command (“USSOCOM”), and others.

Special Operations Command (“USSOCOM”), the U.S.

Air Force, Air Force Material Command (“USAF/AFMC”) and others.

Currently, we have ongoing projects funded, in part, by the U.S.

Army Medical Research Acquisition Activity (“USAMRAA”), the NHLBI, and the USAF/AFMC.

For a complete discussion of the various research grants we have obtained, please refer to the section entitled Government Research Grants included in Item 1 of our Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the SEC on March 10, 2022.

The following additional research grant has been awarded subsequent to the filing of our Annual Report on Form 10-K:

On April 19, 2021, the Company received notification that it received a U.S.

Army Medical Research Acquisition Activity Award (the “USAMRAAA”) entitled "Investigation of a potassium adsorber for the treatment of hyperkalemia induced by traumatic injury and acute kidney injury in austere medicine."

The USAMRAAA Phase II Sequential Award, for up to $1,499,987, was granted to the Company to continue development of two novel and distinct treatment options for life-threatening hyperkalemia.

This award is being funded by the USAMRAAA under Contract No.

W81XWH21C0045.

Research and Development Update

2 unchanged sentences

Our recruiting process is ongoing, so that we can obtain the technical staff required to be able to timely execute on our various grant and non-grant related research and development projects.

As of September 30, 2021, the revenue remaining to be earned on open grant contracts is $11.3 million.

Overall, grant funded programs, HemoDefend-BGA™ (Universal Plasma), HemoDefend-RBC™ and K + ontrol™, continue to progress and have been the beneficiary of approximately $9.6 million, $4.7 million and $7.0 million in total funding, respectively, awarded to date.

The development of our HemoDefend-RBC™ filter, which is designed to remove non-infectious contaminants in transfused packed red blood cells that can cause transfusion reactions, has also been impacted by the COVID-19 pandemic.

The development of this filter

requires the use blood procured from commercial blood banks to perform the validation testing necessary to support an IDE submission.

As of March 31, 2022, the revenue remaining to be earned on open grant contracts is $9.4 million.

Overall, grant funded programs, HemoDefend-BGA™ (Universal Plasma), HemoDefend-RBC™ and K + ontrol™, continue to progress and we have been the beneficiary of approximately $9.6 million, $4.7 million and $7.0 million in total funding, respectively, awarded to date.

The development of our HemoDefend-RBC™ filter, which is designed to remove potassium and non-infectious contaminants in transfused packed red blood cells, has also been impacted by the COVID-19 pandemic.

The development of this filter requires the use blood procured from commercial blood banks to perform the validation testing necessary to support an IDE submission.

Currently, due primarily to the COVID-19 pandemic, the national blood supply is experiencing blood shortages and will not supply blood for research purposes.

2 unchanged sentences

This may delay an IDE submission.

Comparison for the three months ended September 30, 2021 and 2020:

Revenue from product sales was approximately $8,902,000 in the three months ended September 30, 2021, as compared to approximately $10,246,000 in the three months ended September 30, 2020, a decrease of approximately $1,344,000, or 13%.

Comparison for the three months ended March 31, 2022 and 2021:

Revenue from product sales was approximately $7,924,000 in the three months ended March 31, 2022, as compared to approximately $10,143,000 in the three months ended March 31, 2021, a decrease of approximately $2,219,000, or 22%.

This decrease was driven by a decrease in direct sales of approximately $1,971,000 resulting primarily from lower sales in Germany due to COVID-19 pandemic-driven market conditions.

This was driven by a wave in new Delta variant-related COVID-19 cases in Germany, which accelerated through August and has continued to date.

This prompted many hospitals throughout Germany to reduce elective surgical procedures, to reserve ICU beds, and to either maintain or reinstitute restrictions such as visitation rights to non-essential visitors, in preparation of COVID-19 hospitalizations.

However, unlike prior waves in Germany, the rates of severe COVID-19 illness requiring ICU care, and death have been disproportionately very low.

Due to a surge in COVID-19 cases in the first quarter of 2022, many hospitals throughout Germany either maintained or reinstituted restrictions such as visitation rights to non-essential visitors.

However, unlike prior waves in Germany, the rates of severe COVID-19 illness requiring ICU care, and death have been comparatively very low.

This is being partly attributed to high rates of vaccinations that are associated with reduced severity of illness, reduced need for hospitalization, and risk of death.

These factors led to a decrease in both COVID-19 and core non-COVID-19 CytoSorb sales in Germany.

Sales to hospitals in the United States under the EUA granted by the FDA amounted to approximately $577,000 for the three months ended September 30, 2021.

Though difficult to quantitate, we estimate that approximately $1.1 million of total product sales in the third quarter of 2021 was due to the demand for CytoSorb to treat COVID-19 patients.

In addition, the change in the average exchange rate of the Euro to the U.S.

dollar did not have a significant impact on product sales during the three months ended September 30, 2021 as compared to the three months ended September 30, 2020.

Grant income was approximately $859,000 for the three months ended September 30, 2021 as compared to approximately $301,000 for the three months ended September 30, 2020, an increase of approximately $558,000, or 185%.

This increase was a result of the easing of the COVID-19 pandemic in the United States during the three months ended September 30, 2021 and a corresponding increase in grant related work.

During the three months ended September 30, 2020, our research and development employees were either deployed to work-from-home status or reassigned to assist in activities related to increasing the production of CytoSorb.

Total revenues were approximately $9,760,000 for the three months ended September 30, 2021, as compared to total revenues of approximately $10,547,000 for the three months ended September 30, 2020, a decrease of approximately $787,000, or 7%.

Cost of Revenues:

For the three months ended September 30, 2021 and 2020, cost of revenue was approximately $2,463,000 and $2,890,000, respectively, a decrease of approximately $427,000.

Product cost of revenue was approximately $1,642,000 and $2,622,000, respectively, for the three months ended September 30, 2021 and 2020, a decrease of approximately $980,000.

This decrease was due to lower sales and because certain costs associated with the rapid ramp-up of production during the three months ended September 30, 2020 that did not recur during the three months ended September 30, 2021.

Product gross margins were approximately 82% for the three months ended September 30, 2021 as compared to approximately 74% for the three months ended September 30, 2020.

The increase in the gross margin percentage in 2021 was due to manufacturing efficiencies achieved during the three months ended September 30, 2021 and the impact of the ramp-up costs incurred during the three months ended September 30, 2020 that did not recur in 2021.

Research and Development Expenses :

For the three months ended September 30, 2021, research and development expenses were approximately $4,262,000, as compared to approximately $1,753,000 for the three months ended September 30, 2020, an increase of approximately $2,509,000.

This increase was due to an increase in costs associated with our clinical trial activities of approximately $1,578,000, an increase in salaries related to our clinical trial activities of approximately $465,000 due to the hiring of clinical expertise, an increase in rent expense of approximately $328,000 related to rent expense on our new facility and an increase in other research and development labor and other costs of approximately $138,000.

Legal, Financial and Other Consulting Expenses:

Legal, financial and other consulting expenses were approximately $665,000 for the three months ended September 30, 2021, as compared to approximately $580,000 for the three months ended September 30, 2020.

The increase of approximately $85,000 was due to an increase in consulting fees of approximately $95,000, an increase in legal fees of approximately $81,000 and an increase in accounting fees of approximately $12,000.

These increases were offset by a decrease in employment agency fees of approximately $103,000.

Selling, General and Administrative Expenses:

Selling, general and administrative expenses were approximately $7,777,000 for the three months ended September 30, 2021, as compared to approximately $7,282,000 for the three months ending September 30, 2020, an increase of $495,000.

This increase is related to an increase in salaries, commissions and related costs of approximately $296,000, an increase in sales and marketing costs, which include advertising and conference attendance of approximately $499,000, an increase in travel and entertainment costs of approximately $72,000 and an increase in non-cash restricted stock expense of approximately $32,000 related to restricted stock units granted to the Company’s executive officers.

These increases were offset by a decrease in non-cash stock option compensation expense of approximately $90,000, a decrease in royalty expense of approximately $110,000 due to a decrease in sales, a decrease in public relations expense of approximately $73,000 and a decrease in other general and administrative expenses of approximately $131,000.

Interest Income/(Expense), net:

For the three months ended September 30, 2021, net interest income was approximately $13,000, as compared to net interest expense of approximately $261,000 for the three months ended September 30, 2020.

This decrease in net interest expense was the result of the payoff of our outstanding term loans with Bridge Bank in December of 2020.

Gain (Loss) on Foreign Currency Transactions:

For the three months ended September 30, 2021, the loss on foreign currency transactions was approximately $(1,013,000) as compared to a gain of approximately $1,380,000 for the three months ended September 30, 2020.

The loss for the three months ended September 30, 2021 was directly related to the decrease in the spot exchange rate of the Euro to the U.S.

dollar at September 30, 2021 as compared to June 30, 2021.

The spot exchange rate of the Euro to the U.S.

dollar was $1.16 per Euro at September 30, 2021, as compared to $1.18 per Euro at June 30, 2021.

The 2020 gain was directly related to the increase in the spot exchange rate of the Euro at September 30, 2020 as compared to June 30, 2020.

The spot exchange rate of the Euro to the U.S.

dollar was $1.17 per Euro at September 30, 2020, as compared to $1.12 per Euro at June 30, 2020.

Comparison for the nine months ended September 30, 2021 and 2020:

Revenue from product sales was approximately $30,411,000 in the nine months ended September 30, 2021, as compared to approximately $27,922,000 in the nine months ended September 30, 2020, an increase of approximately $2,489,000, or 9%.

This increase was driven by an increase in direct sales of approximately $836,000 resulting from sales to both new customers and repeat orders from existing customers and an increase in distributor sales of approximately $1,653,000.

Sales to hospitals in the United States under the EUA granted by the FDA amounted to approximately $ 1,243,000 for the nine months ended September 30, 2021.

Though difficult to quantitate, we estimate that approximately $4.6 million of total product sales in the nine months ended September 30, 2021 was due to the demand for CytoSorb to treat COVID-19 patients.

In addition, as a result of the increase in the average exchange rate of the Euro to the U.S.

dollar, 2021 product sales were positively impacted by approximately $1,606,000.

For the nine months ended September 30, 2021, the average exchange rate of the Euro to the U.S.

dollar was $1.20 as compared to an average exchange rate of $1.12 for the nine months ended September 30, 2020.

Grant income was approximately $1,973,000 for the nine months ended September 30, 2021 as compared to approximately $1,127,000 for the nine months ended September 30, 2020, an increase of approximately $846,000 or 75%.

This increase was a result of the easing of the COVID-19 pandemic in the United States during the nine months ended September 30, 2021 and a corresponding increase in

grant related work.

During the nine months ended September 30, 2020, our research and development employees were either deployed to work-from-home status or reassigned to assist in activities related to increasing the production of CytoSorb.

Total revenues were approximately $32,383,000 for the nine months ended September 30, 2021, as compared to total revenues of approximately $29,049,000 for the nine months ended September 30, 2020, an increase of approximately $3,334,000 , or 11%.

Sales to hospitals in the United States under the EUA granted by the FDA amounted to approximately $155,000 for the three months ended March 31, 2022 as compared to approximately $304,000 in the first quarter of 2021.

Though difficult to quantify, we estimate that approximately $300,000 of total product sales in the first quarter of 2022 was due to the demand for CytoSorb to treat COVID-19 patients as compared to approximately $1,800,000 in the first quarter of 2021.

In addition, as a result of the decrease in the average exchange rate of the Euro to the U.S.

dollar, 2022 product sales were negatively impacted by approximately $552,000.

For the three months ended March 31, 2022, the average exchange rate of the Euro to the U.S.

dollar was $1.12 as compared to an average exchange rate of $1.21 for the three months ended March 31, 2021.

Grant income was approximately $767,000 for the three months ended March 31, 2022 as compared to approximately $455,000 for the three months ended March 31, 2021, an increase of approximately $312,000 or 68%.

This increase was a result of the easing of the COVID-19 pandemic in the United States during the three months ended March 31, 2022 and a corresponding increase in grant related work.

During the three months ended March 31, 2021, our research and development employees were either deployed to work-from-home status or reassigned to assist in activities related to increasing the production of CytoSorb.

Total revenues were approximately $8,691,000 for the three months ended March 31, 2022, as compared to total revenues of approximately $10,599,000 for the three months ended March 31, 2021, a decrease of approximately $ 1,907,000, or 18%.

Cost of Revenues:

For the nine months ended September 30, 2021 and 2020, cost of revenue was approximately $7,925,000 and $8,525,000, respectively, a decrease of approximately $600,000.

Product cost of revenue was approximately $6,068,000 and $7,500,000, respectively, for the nine months ended September 30, 2021 and 2020, a decrease of approximately $1,432,000.

This decrease was related to certain costs associated with the rapid ramp-up of production during the period ended September 30, 2020 that did not recur during the period ended September 30, 2021.

These decreases were offset by the negative impact of non-recurring costs related to prior years tariffs as a result of an audit by the German Customs Authorities of approximately $732,000 and the offsetting non-recurring positive impact of the Employee Retention Tax Credit of approximately $388,000, both of which were recorded in the first quarter of 2021.

Product gross margins were approximately 80% for the nine months ended September 30, 2021 compared to approximately 73% for the nine months ended September 30, 2020.

For the three months ended March 30, 2022 and 2021, cost of revenue was approximately $2,278,000 and $2,751,000, respectively, a decrease of approximately $474,000.

Product cost of revenues decreased approximately $776,000 during the three months ended March 31, 2022 as compared to the three months ended March 31, 2021 primarily as a result of decreased sales.

Product gross margins were approximately 80% for the three months ended March 31, 2022 as compared to approximately 77% for the three months ended March 31, 2021.

The increase in the gross margin percentage in 2022 was due the impact of non-recurring costs related to prior years tariffs as a result of an audit by the German Customs Authorities of approximately $732,000 in the three months ended March 31, 2021 that did not recur in 2022.

Research and Development Expenses :

For the nine months ended September 30, 2021, research and development expenses were approximately $10,244,000 as compared to research and development expenses of approximately $6,125,000 for the nine months ended September 30, 2020, an increase of approximately $4,119,000.

This increase was due to an increase in costs associated with our clinical trial activities of approximately $2,035,000, an increase in salaries related to our clinical trial activities of approximately $1,304,000 due to the hiring of clinical expertise, an increase in rent expense of approximately $509,000 related to rent expense on our new facility and an increase in other research and development labor and other costs of approximately $271,000.

For the three months ended March 31, 2022, research and development expenses were approximately $4,243,000 as compared to research and development expenses of approximately $2,282,000 for the three months ended March 31, 2021, an increase of approximately $1,961,000.

This increase was due to an increase in costs associated with our clinical trial activities of approximately $1,410,000, an increase in salaries related to our clinical trial activities of approximately $187,000 due to the hiring of clinical expertise, an increase in rent expense of approximately $65,000 related to rent expense on our new facility, an increase in other research and development labor costs of approximately $102,000 related to the hiring of additional scientific expertise and an increase in other research and development costs of approximately $197,000.

Legal, Financial and Other Consulting Expenses:

Legal, financial and other consulting expenses were approximately $2,090,000 for the nine months ended September 30, 2021, as compared to approximately $1,945,000 for the nine months ending September 30, 2020.

The increase of approximately $145,000 was due to an increase an increase in consulting fees of approximately $244,000.

These increases were offset by decreases in legal fees of approximately $76,000 and accounting fees of approximately $23,000.

Legal, financial and other consulting expenses were approximately $801,000 for the three months ended March 31, 2022, as compared to approximately $708,000 for the three months ended March 31, 2021.

The increase of approximately $93,000 was due to an increase in legal fees of approximately $324,000 due to the abandonment of certain patent applications and an increase in audit fees of approximately $83,000.

These increases were offset by decreases in employment agency fees of approximately $255,000 and consulting fees of approximately $59,000.

Selling, General and Administrative Expenses:

Selling, general and administrative expenses were approximately $25,308,000 for the nine months ended September 30, 2021, as compared to $20,190,000 for the nine months ended September 30, 2020, an increase of $5,118,000.

This increase is related to an increase in salaries, commissions and related costs of approximately $2,994,000, an increase in royalty expenses of approximately $201,000 due to the increase in product sales, and an increase in non-cash restricted stock expense of approximately $881,000 related to restricted stock units granted to the Company’s executive officers, an increase in non-cash stock option compensation expense of approximately $360,000, an increase in commercial insurance of approximately $209,000, an increase in sales and marketing costs, which include advertising and conference attendance and other general and administrative expenses of approximately $536,000 and an increase in other general and administrative costs of approximately $54,000.

These increases were offset by a decrease in travel and entertainment costs of approximately $117,000 due primarily to travel restrictions related to the COVID-19 pandemic.

Interest Income/(Expense), net:

For the nine months ended September 30, 2021, interest income was approximately $16,000, as compared to interest expense of approximately $840,000 for the nine months ended September 30, 2020.

This decrease in net interest expense of approximately $856,000 was the result of the payoff of our outstanding term loans with Bridge Bank in December of 2020.

Selling, general and administrative expenses were approximately $9,161,000 for the three months ended March 31, 2022, as compared to approximately $7,710,000 for the three months ending March 31, 2021, an increase of $1,451,000.

This increase is related to an increase in salaries, commissions and related costs of approximately $936,000, an increase in occupancy costs of approximately $373,000 related to rent on our new facility in Princeton, NJ, an increase in sales and marketing costs, which include advertising and conference attendance of approximately $286,000, an increase in travel and entertainment costs of approximately $153,000 and an increase in non-cash stock option compensation expense of approximately $120,000 and an increase in commercial insurance costs of approximately $86,000.

These increases were offset by a decrease in non-cash restricted stock expense of approximately $283,000, a decrease in royalty expense of approximately $183,000 due to a decrease in sales, a decrease in public relations consulting expense of approximately $73,000 and a decrease in other general and administrative expenses of approximately $37,000.

Gain (Loss) on Foreign Currency Transactions:

For the nine months ended September 30, 2021, the loss on foreign currency transactions was approximately $(2,084,000) as compared to a gain of approximately $1,417,000 for the nine months ended September 30, 2020.

The loss for the nine months ended September 30, 2021 was directly related to the decrease in the spot exchange rate of the Euro to the U.S.

dollar at September 30, 2021 as compared to December 31, 2020.

For the three months ended March 31, 2022, the loss on foreign currency transactions was approximately $1,213,000 as compared to a loss of approximately $1,306,000 for the three months ended March 31, 2021.

The 2022 loss was directly related to the decrease in the spot exchange rate of the Euro to the U.S.

dollar as of March 31, 2022 as compared to December 31, 2021.

The spot exchange rate of the Euro to the U.S.

dollar was $1.16 per Euro at September 30, 2021, as compared to $1.22 per Euro at December 31, 2020.

The 2020 gain was directly related to the increase in the spot exchange rate of the Euro at September 30, 2020 as compared to December 31, 2019.

dollar was $1.11 per Euro as of March 31, 2022, as compared to $1.14 per Euro as of December 31, 2021.

The 2021 loss was directly related to the decrease in the spot exchange rate of the Euro as of March 31, 2021 as compared to December 31, 2020.

The spot exchange rate of the Euro to the U.S.

dollar was $1.17 per Euro at September 30, 2020, as compared to $1.12 per Euro at December 31, 2019.

dollar was $1.17 per Euro as of March 31, 2021, as compared to $1.22 per Euro at December 31, 2020.

History of Operating Losses

We have experienced substantial operating losses since inception.

As of September 30, 2021, we had an accumulated deficit of approximately $211,878,000, which included losses of approximately $15,252,000 and $ 7,159,000 for the nine-month periods ended September 30, 2021 and 2020, respectively.

As of March 31, 2022, we had an accumulated deficit of approximately $230,152,000, which included losses of approximately $8,966,000 and $4,168,000 for the three-month periods ended March 31, 2022 and 2021, respectively.

Historically, losses have resulted principally from costs incurred in the research and development of our polymer technology, clinical studies, and general and administrative expenses.

1 unchanged sentence

Since inception, our operations have been primarily financed through the issuance of debt and equity securities.

As of September 30, 2021, we had current assets of approximately $72,752,000 including cash on hand of approximately $61,043,000 and current liabilities of approximately $11,070,000.

During the period from January 1, 2020 through July 15, 2020, we raised approximately $26,427,000 by utilizing our ATM facility with co-agents Jefferies LLC and B.

In addition, we received net proceeds of approximately $53,800,000 from our underwritten public offering that closed on July 24, 2020.

Also, we received approximately $1,127,000 in cash from the approved sale of our net operating losses and research and development credits from the State of New Jersey during the nine months ended September 30, 2021.

We believe that we have sufficient cash to fund our operations well into the future.

As of March 31, 2022, we had current assets of approximately $55,854,000 including unrestricted cash on hand of approximately $43,023,000 and current liabilities of approximately $14,672,000.

As of March 31, 2022, $25 million of our total shelf amount was allocated to our ATM facility, all of which is still available.

In addition, we have $15 million of debt availability, providing financial flexibility, if needed.

In April of 2022, we received approximately $740,000 in cash from the approved sale of our net operating losses and research and development credits from the State of New Jersey.

We are also managing our resources proactively, continuing to invest in key areas such as our U.S.

pivotal STAR-T and STAR-D trials.

In April 2022, we began instituting tighter cost controls which are expected to reduce our planned cash burn by an additional $2 million per quarter.

We believe that we have sufficient cash to fund the Company’s operations beyond twelve months from the issuance of these financial statements.

COVID-19 Impact on Financial Results

Product revenues in the three months ended September 30, 2021 were negatively impacted by pandemic-driven adverse market conditions, especially in Germany which is our largest market.

This was driven by a wave in new COVID-19 cases in Germany, driven by the Delta variant, which accelerated through August and, after peaking in mid-September, has continued to date.

Product revenues in the three months ended March 31, 2022 were negatively impacted by pandemic-driven adverse market conditions, especially in Germany which is our largest market.

This was due to another wave in new COVID-19 cases in Germany, driven by the Omicron variant, which peaked in March.

This prompted many hospitals throughout Germany to either maintain or reinstitute restrictions such as visitation rights to non-essential visitors.

However, unlike prior waves in Germany, the rates of severe COVID-19 illness requiring ICU care, and death have been disproportionately very low.

This is being partly attributed to high rates of vaccinations that are associated with reduced severity of illness, reduced need for hospitalization, and risk of death.

Our product revenues decreased by 13% during the three months ended September 30, 2021 to approximately $8.9 million from approximately $10.2 million in the three months ended September 30, 2020.

Though difficult to quantitate, we estimate that approximately $1.1 million of our product revenues were directly or indirectly related to COVID-19 during the three-month period ended September 30, 2021 as compared to $2.7 million during the three months ended September 30, 2020.

Given the order patterns we are currently experiencing, we expect the COVID-19 pandemic will have a similar impact on product revenues in the fourth quarter of 2021.

COVID-19 revenues are expected to decline in future periods, as increasing vaccinations globally result in fewer new cases, hospitalizations, and deaths from COVID-19.

These expectations may change depending on whether there is a resurgence of COVID-19, or a containment of the pandemic.

Our product revenues decreased by 22% during the three months ended March 31, 2022 to approximately $7.9 million from approximately $10.1 million in the three months ended March 31, 2021.

Though difficult to quantify, we estimate that approximately $300,000 of our product revenues were directly or indirectly related to COVID-19 during the three-month period ended March 31, 2022 as compared to $1.8 million during the three months ended March 31, 2021.

We expect that COVID-19 revenues will continue to decline in future periods, as increasing vaccinations globally result in fewer new cases, hospitalizations, and deaths from COVID-19.

As the COVID-19 pandemic wains, these expectations may change depending on whether there is a resurgence of COVID-19, or a containment of the pandemic.

In addition, as a result of the EUA granted by the FDA on April 11, 2020, we began shipping CytoSorb to hospitals in the United States.

Sales to hospitals in the United States under the EUA amounted to approximately $577,000 and $1,243,000 for the three and nine months ended September 30, 2021, respectively.

We are continuing to receive inquiries and orders for CytoSorb.

However, at this time, we cannot predict the overall impact U.S.

sales will have on our overall product sales during the remainder of 2021.

Sales to hospitals in the United States under the EUA amounted to approximately $155,000 for the three months ended March 31, 2022.

Given the significant decrease in COVID-19 cases in the U.S.

at this time, we do not believe that U.S.

sales under FDA EUA will have a significant impact on our overall product sales during the remainder of 2022.

The COVID-19 pandemic had generally been a positive driver for CytoSorb sales and it has highlighted the use of CytoSorb to treat cytokine storm and hyperinflammation.

1 unchanged sentence

We believe this awareness of CytoSorb increased overall usage during the COVID-19 pandemic and could help drive further CytoSorb sales in the future.

However, since the beginning of the COVID-19 pandemic, we have experienced disruptions to our normal sales processes, which disruptions have been amplified more recently in Germany as a result of a wave of new COVID-19 cases.

For example, we have experienced decreased access of our sales representatives to hospitals and fewer sales meetings with physicians, decreased effectiveness of virtual medical conferences, and limits on our ability to market new indications, such as ticagrelor and rivaroxaban removal.

However, since the beginning of the COVID-19 pandemic, we have experienced disruptions to our normal sales processes.

These disruptions have been amplified more recently in Germany as a result of a wave of new COVID-19 cases.

For example, we have experienced decreased access of our sales representatives to hospitals and fewer sales meetings with physicians, approximately 40% of our direct salesforce in Germany contracting COVID-19 during Q1, decreased effectiveness of virtual medical conferences, and limits on our ability to market new indications, such as ticagrelor and rivaroxaban removal.

Additionally, hospitals have reduced the number of surgeries and other non-COVID-19 hospitalized patients and slowed our ability to generate clinical data to support our sales and marketing efforts.

These factors negatively impacted our critical care and cardiac surgery markets in Germany, resulting in lower-than-expected sales of CytoSorb during the third quarter ended September 30, 2021.

These factors negatively impacted our critical care and cardiac surgery markets in Germany, resulting in lower-than-expected sales of CytoSorb during the quarter ended March 31, 2022.

With the pandemic in flux, it is difficult to predict what the near-term impact of COVID-19 will have on overall ongoing product sales.

Grant income was negatively impacted by the COVID-19 pandemic during 2020 and the first half of 2021.

Our research and development employees were either deployed to work-from-home or reassigned to assist in production activities to increase production of CytoSorb.

We would expect over time to regain unrestricted access to hospitals and physicians which should positively impact our product sales in the future.

The COVID-19 pandemic did not impact grant income during the first quarter of 2022 but did negatively impact first quarter 2021 results, when our research and development employees were either deployed to work-from-home or reassigned to assist in production activities to increase production of CytoSorb.

Currently, the team is executing upon our grant contracts.

Our grant income increased by 285% during the three months ended September 30, 2021 as compared to the three months ended September 30, 2020.

However, this may change depending on whether there is a resurgence of COVID-19.

As a result, grant income may be reduced until such time as the pandemic is over, however, this reduction is not expected to have a material impact on our financial results because of the low gross margins associated with grant activities.

Our grant income increased by 68% during the three months ended March 31, 2022 as compared to the three months ended March 31, 2021.

However, this may change depending on whether there is a resurgence of COVID-19, which may result in a reduction of grant income until such time as the pandemic is over, however, this reduction is not expected to have a material impact on our financial results because of the low gross margins associated with grant activities.

There has been a worldwide slowdown in clinical trial activities as medical providers focus on COVID-19 patients.

1 unchanged sentence

In addition, because of ongoing COVID-19-related delays in the U.K., we elected to stop our TISORB single arm trial in April 2021, in favor of dedicating those resources to the U.S.

STAR-T randomized controlled trial in the United States which has begun enrollment.

STAR-T randomized controlled trial in the United States which is currently enrolling.

These clinical trial activities and related expenses are expected to increase substantially as the impact of the COVID-19 pandemic continues to ease, especially in the U.S.

1 unchanged sentence

It is uncertain when these complex headwinds on health care delivery and clinical research activities will resolve and until then these factors may result in reduced capabilities of institutions to contribute patient recruitment into clinical trials with the potential to slow enrollment in our Company-sponsored clinical trials.

In addition, certain of our third quarter 2021 selling, general, and administrative expenses, such as travel and conference expenses, were lower than pre-COVID-19 levels due to the continuing restrictions on travel and the cancelling of medical and investor conferences during the pandemic.

In addition, certain of our selling, general, and administrative expenses, such as travel and conference expenses, continue to be lower than pre-COVID-19 levels due to the continuing restrictions on travel and the cancelling of medical and investor conferences during the pandemic.

This is also a temporary situation which is not expected to continue once the pandemic is contained.

5 unchanged sentences

The Initial Early Term began on the commencement date (April 1, 2021) and lasted two months.

The Early Term commenced on June 1, 2021 and lasts until the date of issuance of the certificate of occupancy for the manufacturing space (expected to be September 30, 2021).

The Early Term commenced on June 1, 2021 and lasted until September 30, 2021.

The lease also contains two five-year renewal options.

Commencing on the date of the receipt of the certificate of occupancy (September 30, 2021), the remaining lease term will last for 15.5 years.

Commencing on September 30, 2021, the remaining lease term will last for 15.5 years.

The lease requires monthly rental payments of $25,208 for the Initial Early Term, $88,254 for the Early Term and initial monthly payments of approximately $111,171 in the first year of the remaining term.

25 unchanged sentences

We have no off-balance sheet arrangements.

Critical Accounting Policies and Estimates

A discussion of our critical accounting policies and estimates is contained in our Annual Report on Form 10-K.

Going Concern

2 unchanged sentences

Gross proceeds from the Offering amounted to approximately $57.5 million and, after deducting the underwriting discounts and commissions and expenses related to the Offering, the Company received total net proceeds of approximately $53.8 million.

As of September 30, 2021, the Company’s cash balance was approximately $61 million, which the Company expects will fund the Company’s operations well beyond the next twelve months from the date of issuance of these financial statements.

As a result, the Company continues to assert that the going concern risk has been substantially mitigated.

As of March 31, 2022, the Company’s cash and cash equivalents and restricted cash were approximately $44.7 million, which the Company expects will fund the Company’s operations beyond twelve months from the issuance of these financial statements.

As a result, the Company has determined that the going concern risk has been substantially mitigated.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 2. Management’s Discussion and Analysis